Guerbet wins Drug Shortage Assistance Award from FDA

Guerbet, a pioneer in the field of contrast agents for medical imaging, has received a Drug Shortage Assistance Award from the U.S. Food and Drug Administration for its assistance in preventing or alleviating a drug shortage.

Guerbet is being recognized for its efforts related to the shortage of Ethiodol (ethiodized oil) injection, including acquiring the new drug application, submitting several post-approval supplements to restart manufacturing with acceptable compliance records, and to market the product for a well-known and medically necessary indication in the United States. These actions by Guerbet resolved a critical drug shortage affecting patients with cancer.

Ethiodol (ethiodized oil) injection, now under the tradename of Lipiodol®, is an oil-based radiopaque contrast agent used to image tumors in patients with certain types of cancer.

Through the Drug Shortage Assistance Award program, FDA recognizes companies for making a substantial contribution to preventing or alleviating a critical drug shortage. This award also recognizes companies for their commitment to public health, as well as a commitment to quality manufacturing.

"We are pleased that the FDA recognizes our commitment to ensuring U.S. patients have access to the medications they need," commented Yves L'Epine, CEO of Guerbet.

Drug shortages pose a substantial public health threat, delaying, and in some cases even denying, critically needed care for patients. Working with drug manufacturers, the FDA helped prevent over 280 drug shortages in 2012 and 170 in 2013.

There were 44 new drug shortages in 2013, down from 117 new drug shortages in 2012. Two key prevention strategies have helped drive this significant decrease in new shortages: 1) early notification and 2) a focus on quality manufacturing.

FDA is committed to working with companies, like Guerbet, to prevent and mitigate drug shortages.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
FDA approval of lifileucel: A milestone in tumor-infiltrating lymphocyte therapy for advanced melanoma